Citi downgraded Calliditas Therapeutics (CALT) to Neutral from Buy with a $39 price target after Asahi Kasei (AHKSY) announced an agreement to acquire Calliditas for about $39 per ADS or about $1.1B.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- CHMP Endorses Calliditas’ Kinpeygo for IgAN
- Calliditas Therapeutics downgraded to Hold from Buy at Jefferies
- Calliditas Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Calliditas Therapeutics downgraded to Hold from Buy at Stifel
- Calliditas Therapeutics presents data at European Renal Association Congress